Direct Oral Anticoagulant Use: A Practical Guide to Common
irect oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the preven- tion of thrombosis in several cardiovascular contexts.1
Direct Oral Anticoagulant Use: A Practical Guide to Common
Direct oral anticoagulants (DOACs)—dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), and betrixaban (Bevyxxa) are anticoagulation pharmacotherapy used for the prevention of thrombosis in several cardiovascular contexts. 1 DOACs are categorized into 2 main classes: oral direct factor Xa inhibitors (ie,
Direct Oral Anticoagulant Use: A Practical Guide to Common
DOACs are indicated for prevention and treatment of several cardiovascular conditions. Since the first approval in 2010, DOACs have emerged as leading therapeutic alternatives that provide both clinicians and patients with more effective, safe, and convenient treatment options in thromboembolic settings.
Direct Oral Anticoagulant Use: A Practical Guide to Common
Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long-standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions. Since the first approval in 2010, DOACs have emerged a
Management of Anticoagulation Therapy - American Society
Several anticoagulant options are available including vitamin K-antagonists (VKAs) such as warfarin, and direct oral anticoagulants (DOACs) such as dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban. Each anticoag-ulant medication has unique dosing and monitoring requirements that can be
- What is a direct oral anticoagulant?
- Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long‐standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular conditions. ...
- Are DOACs an alternative to low-molecular-weight heparins and warfarin?
- on Forum Management of DOACsOVERVIEWThe introduction of DOACs as an alternative to low-molecular-weight heparins (LMWH) and warfarin requires health care organizations to modify existing protocols and use evidence-based practice guidelines to address the initiation and maintenance of all anticoagulation
- Does rapid onset of a DOAC reduce the risk of subtherapeutic anticoagulation?
- nefit as medication-compliant patients. Conversely, the rapid onset of the DOACs does ensure therapeutic anticoagulation as soon as the DOAC dose is taken, theoretically minimizing the w ndow of subtherapeutic anticoagulation. These considerations should be weighed with the potential risk
- Are direct oral anticoagulants a good alternative to vitamin K antagonist?
- ABSTRACT: Direct oral anticoagulants (DOACs) have quickly become attractive alternatives to the long- standing standard of care in anticoagulation, vitamin K antagonist. DOACs are indicated for prevention and treatment of several cardiovascular con-ditions.
- When are DOACs approved?
- DOACs are approved in three major clinical settings where oral anticoagulation is commonly used, but are not preferred over warfarin for certain patient populations and are contraindicated for others (see the Initiating a DOAC section below for more information).
- How do I switch from a non-warfarin anticoagulant to a DOAC?
- m non-warfarin anticoagulant to a DOAC:When switching from a DOAC to a different DOAC or from LMWH/fondaparinux to a DOAC, start the new DOAC at the next scheduled administration of the original anticoagulant and then
